Would you consider adding encorafenib + cetuximab to adjuvant mFOLFOX for a patient with oligometastatic colon cancer with BRAF V600E mutation s/p metastasectomy and primary resection given the new data from the BREAKWATER trial?   

This is a compelling question, and I agree with many of the points made by the other respondents. In a patient with metastatic, completely resected BRAF-mutated colon cancer, I would consider using a ctDNA minimal residual disease assay (such as Signatera) to inform decision making. If the patient i...

Great question without clear evidence. Given the generally poor clinical outcomes for patients with BRAF V600E-mutated metastatic colorectal cancer, metastasectomy is not commonly offered unless the patient shows prolonged disease response/stability on maintenance treatment. We still have very few ...

While the prognosis for patients with resected stage IV BRAF V600E-mutant colorectal cancer remains poor despite adjuvant FOLFOX, emerging data—such as the significantly higher response rates seen with FOLFOX plus encorafenib and cetuximab in the first-line metastatic setting (as demonstrated ...